Page last updated: 2024-08-25

hederagenin and paclitaxel

hederagenin has been researched along with paclitaxel in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (57.14)24.3611
2020's3 (42.86)2.80

Authors

AuthorsStudies
Chen, Z; Cui, Y; Duan, H; Feng, Y; Han, L; Tong, X; Yang, S; Zhu, Y1
Bi, Y; Fu, FH; Lei, L; Liu, JQ; Liu, XX; Luo, XM; Wang, HB; Wang, KY; Wang, X; Yang, YT; Zhai, R1
Chen, Z; Duan, H; Han, L; Hsu, P; Lee, KH; Liu, W; Morris-Natschke, SL; Tong, X; Yang, S1
Chen, Z; Cheng, YY; Duan, HQ; Goto, M; Huang, KY; Lee, KH; Ling, Y; Liu, YL; Morris-Natschke, SL; Tong, XH; Yang, PC; Yang, SL1
Bi, Y; Chen, X; Huang, W; Li, X; Liang, K; Liu, S; Ma, M; Wang, B; Wang, H; Zeng, W1
Bi, Y; Cheng, H; Huang, W; Liu, S; Qiao, H; Tian, Q; Wang, H; Wang, L; Wang, R; Wang, Y; Xu, S1
Chan, MT; Chen, B; Du, B; Gu, J; Ho, IH; Liu, Q; Liu, X; Tan, Y; Wang, K; Wei, X; Wu, WK; Xiao, J; Yin, T; Zhan, Y; Zhang, L; Zhang, W1

Other Studies

7 other study(ies) available for hederagenin and paclitaxel

ArticleYear
The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
    European journal of medicinal chemistry, 2017, Mar-31, Volume: 129

    Topics: A549 Cells; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Hemolysis; Humans; Pulsatilla; Saponins; Structure-Activity Relationship

2017
Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
    European journal of medicinal chemistry, 2017, Dec-01, Volume: 141

    Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Oleanolic Acid; Structure-Activity Relationship; Tumor Cells, Cultured

2017
Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
    Journal of natural products, 2018, 03-23, Volume: 81, Issue:3

    Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cytotoxins; Erythrocytes; G1 Phase; Hemolysis; Humans; KB Cells; Lung Neoplasms; MCF-7 Cells; Rabbits; Saponins; Structure-Activity Relationship

2018
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
    Journal of natural products, 2019, 11-22, Volume: 82, Issue:11

    Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitric Oxide; Nitric Oxide Donors; Oleanolic Acid; Protein Kinase Inhibitors

2019
Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Molecular Structure; Oleanolic Acid; Structure-Activity Relationship

2021
Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
    European journal of medicinal chemistry, 2022, Mar-15, Volume: 232

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Nitrogen; Oleanolic Acid

2022
Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells.
    Cell death & disease, 2020, 08-13, Volume: 11, Issue:8

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Cisplatin; Humans; Lung Neoplasms; Lysosomes; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Oleanolic Acid; Paclitaxel; Reactive Oxygen Species; Xenograft Model Antitumor Assays

2020